
Targeted mRNA Nanoparticles Rally Immune Attack on Tumors
Scientists developed 'smart' antibodies-guided nanoparticles that deliver mRNA encoding CXCL9, plus a immune-stimulating drug, directly to tumor-associated macrophages. This reactivates anti-tumor T cells and slows tumor growth in mice, with increased CXCL9 and NOS2 signals and a drop in immunosuppressive macrophages. When combined with immune checkpoint inhibitors, the immune landscape changed—though tumor size didn’t further shrink. While promising as a proof of concept for targeted cancer immunotherapy, safety and efficacy in humans still need thorough testing.













